BASKING RIDGE, New Jersey, October 8, 2020 (GLOBE NEWSWIRE) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or “Company”), a clinical-level biopharmaceutical company committed to the progression of mobile treatments designed to not manage the disease, announced that it had opened its CLBS119 proof-of-concept test as a remedy for COVID-19-induced lung lesions and began deciding on potential patients for inclusion in NYU Langone Health. it is designed to compare the protection and efficacy of a single treatment of CLBS119 (mobile CD34 autologous peripheral blood derivatives) for the remedy and repair of COVID-19-induced lung lesions in adults. an earlier SARS-CoV-2 infection that requires more oxygen.
“Evidence suggests that severe lung damage due to COVID-19 would possibly result in long-term disability due to vascular damage. Although many treatments target SARS-CoV-2 or severe inflammation relief caused by the virus in the acute phase of the disease, no treatment has been shown to address long-term lung damage induced by COVID-19,” said Douglas W. Losordo, MD, FACC, FAHA, Caladrius’ medical director. “In previous clinical trials and preclinical models, CD34 cells have consistently shown evidence of vascular repair in various organs, adding models of severe lung damage. This clinical examination of CLBS119 will address the significant unmet medical need of COVID-19 survivors who still require oxygen supplements. Our speculation is that CD34 cells can regenerate Blood vessels were injured through COVID-19, thus restoring lung function and capacity and cutting or eliminating the need for more oxygen.
About Caladrius Biosciences
Caladrius Biosciences, Inc. es a clinically level biopharmaceutical company committed to the progression of mobile treatments designed to reverse the disease, not to control it. We expand premium mobile treatment products based on the perception that our body comprises finely adjusted self-healing mechanisms. . Our generation exploits and puts into operation these mechanisms in the form of express mobiles, forms and modes of management unique to each medical indication.
The company’s existing candidate products come with CLBS119, a cd34 candidate mobile cure product for the repair of lung pain in COVID-19 patients suffering from respiratory failure, for which the company recently submitted a clinical trial, as well as 3 Developmental remedies for ischemic diseases. based on its CD34 mobile healing platform: HONEDRA® (formerly CLBS12), holder of the SAKIGAKE designation and eligible for early conditional approval in Japan for the remedy of critical limb ischemia (“CLI”) based on the effects of a ongoing clinical trial; CLBS16, the subject of a recently completed positive phase 2a clinical trial in the United States and scheduled to initiate a full phase 2b trial in the United States 4T20 for the remedy of coronary microvascular disorder (“CMD”); and CLBS14, a designated cure for complex regenerative medicine cure (“RMAT”) for which the company has finalized with the US Food and Drug Administration (the “FDA”) a protocol for a trial of confirmation of phase 3 in subjects without refractory disability without angina option (“NORDA”). For more information about the company, visit www. caladrius. com.
Contact:
Media: W2O Group Christiana Pascale Phone: 1-212-257-6722 Email: cpascale@w2ogroup. com